Tidepool, a 501(c)3 nonprofit committed to empowering the next generation of innovations in diabetes management, today announced the FDA clearance of Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in persons six years of age and greater.
“I’d also like to personally acknowledge and celebrate the contributions of the DIY community and participants in the Loop Observational Study conducted by the JAEB Center for Health Research who made this milestone possible.”
Tidepool Loop, a patient-led project, is the first application of its kind to receive clearance from the FDA and is also the first to enable insulin delivery from a compatible Apple Watch. The algorithm technology in Tidepool Loop is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend and deliver correction boluses when glucose values are predicted to exceed predefined thresholds.
“We knew this day would come, but we couldn’t have achieved it without the support of the entire diabetes community, including the FDA,” said Howard Look, CEO, and co-founder of Tidepool. “I’d also like to personally acknowledge and celebrate the contributions of the DIY community and participants in the Loop Observational Study conducted by the JAEB Center for Health Research who made this milestone possible.”
Tidepool Loop can now serve as a predicate device for future interoperable Automated Insulin Dosing (AID) submissions, providing a more clearly defined pathway through the regulatory process. This work was supported by grants from JDRF, The Helmsley Charitable Trust, the Tullman Foundation, and a diverse community of individual funders impacted by their experience with diabetes.
With the clearance of Tidepool Loop, the organization is now finalizing agreements with device partners to create a seamless experience for both physicians prescribing Tidepool Loop and the patients using it. Though Tidepool’s initial launch device partners have not been announced, the company has a development partnership with Dexcom and additional yet-to-be-named medical device companies for future inclusion of their components with the Tidepool Loop platform.
What pumps will this be compatible with? I currently use a Medtronic 670G which will NOT share real time data, thus it is worthless to loop with.
I truly hope you offer better options. All the best, Jack
The pump partner hasn’t been named yet. Should be interesting!
Oh that is very exciting. I hope it will compete with Dialoop in the US. Perhaps approval for Tidepool will cause DIaloop to finally enter the market.
I just heard that Diabeloop might be pairing with Korea’s EoFlow patch pump with just filed with the FDA. If I can’t have Diabeloop with Kaleido, I’d love EoFlow!!!